Clinical Trial for the Safety and Efficacy of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Anti-CD19 chimeric-antigen-receptor-T-cell-therapy-Yake-Biotechnology (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
Most Recent Events
- 07 Sep 2020 New trial record